Financial Data and Key Metrics Changes - The company reported a record revenue of $40.8 million, representing a 10% increase compared to the prior period [9][21] - Annual recurring revenue (ARR) reached $28.5 million, up 31% year-over-year, marking the first time the company provided ARR at a specific point in time [10][23] - The company achieved a record underlying EBITDA of $5.1 million, an improvement of $8.5 million over the previous year [12] - Positive operating cash flow of $5.8 million was generated during the year, a turnaround of $12.9 million from the prior year [13][29] Business Line Data and Key Metrics Changes - The company signed new total contract value (TCV) of $73.8 million, more than doubling the previous year's figures [12][30] - The UK market contributed 63% of total revenue, surpassing the ANZ region for the first time [25] - The modular architecture of the Mya Precision platform allows for incremental sales without extensive implementation efforts, enhancing customer flexibility [5][39] Market Data and Key Metrics Changes - The company operates in three main geographies: Australia, New Zealand, and the United Kingdom, with plans for potential expansion into Canada, Saudi Arabia, and the UAE [6][42] - The company has seen significant investment and attention in patient flow solutions, which are critical for hospital administrators [34] Company Strategy and Development Direction - The company aims to scale existing core products and markets, particularly in EPR flow and virtual care opportunities [42] - There is a focus on leveraging Mya Precision capabilities in other health verticals such as aged care and community care [42] - The company is exploring mergers and acquisitions that are strategic and synergistic in nature [43] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth trajectory, highlighting the importance of customer referenceability and the modular sales strategy [34][39] - The company anticipates continued growth in contracted revenue and expects EBITDA and positive operating cash flow for FY 2026 [41] Other Important Information - The company appointed new directors with extensive healthcare executive experience to strengthen its leadership team [15][17] - The North Cumbria contract, valued at over $39 million over ten years, is a significant milestone for the company [35] Q&A Session Summary Question: Can you provide more detail on the structure of capital license purchases? - The capital license includes an upfront component for a ten-year period, with ongoing support and maintenance fees that are annually recurring [46][47] Question: What does the pipeline look like for new contracts? - The pipeline continues to build due to customer deployments and market opportunities, but specific contract timelines cannot be predicted [48][49] Question: What are the expectations around staffing and expenses moving forward? - Staffing levels are expected to remain stable, with investments in sales and marketing capabilities [52][53] Question: How does the company plan to ensure future M&A activities deliver value to shareholders? - The company evaluates M&A opportunities based on valuation, expected returns, and support for future growth [55] Question: Should we expect gross margin expansion in FY 2026? - Gross margin expansion is expected to continue as ARR increases, barring any significant changes in product mix [57] Question: What is the opportunity in the UK market? - The UK market presents significant opportunities for digitization and modular solutions, although exact dollar values are uncertain [59][60] Question: Can the company offer trial software to new markets? - The company has successfully used trial software in the past to enter new markets and may consider similar approaches in the future [61][63]